PV 707

Drug Profile

PV 707

Latest Information Update: 01 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CRC for Tissue Growth and Repair (CEASED)
  • Developer CRC for Tissue Growth and Repair (CEASED); GroPep
  • Class
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Burns

Most Recent Events

  • 01 Dec 2003 Discontinued - Phase-II for Burns in Australia (Topical)
  • 18 Jul 2001 Phase-II clinical trials for Burns in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top